From 1985 to 2001, the Burch-Schneider antiprotrusio cage (B-S APC) was implanted in 57 cases (55 patients) with massive acetabular deficiency. The B-S APC survived until the last review 5 to 21 years after operation in 89.5% of the cases, produced substantial pain relief, and increased range of hip motion and walking capacity. The 10.5% failure rate was due to aseptic loosening in 2 cases and mechanical failure in 4 cases. It appears that application of the B-S APC in extensive acetabular deficiency presents a durable solution provided that proper indications and technique are used.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.arth.2007.10.009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
scTrends: A living review of commercial single-cell and spatial 'omic technologies.
Cell Genom
December 2024
Relation Therapeutics, London, UK. Electronic address:
Understanding the rapidly evolving landscape of single-cell and spatial omic technologies is crucial for advancing biomedical research and drug development. We provide a living review of both mature and emerging commercial platforms, highlighting key methodologies and trends shaping the field. This review spans from foundational single-cell technologies such as microfluidics and plate-based methods to newer approaches like combinatorial indexing; on the spatial side, we consider next-generation sequencing and imaging-based spatial transcriptomics.
View Article and Find Full Text PDFThe epithelial barrier theory and its associated diseases.
Allergy
December 2024
Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.
The prevalence of many chronic noncommunicable diseases has been steadily rising over the past six decades. During this time, over 350,000 new chemical substances have been introduced to the lives of humans. In recent years, the epithelial barrier theory came to light explaining the growing prevalence and exacerbations of these diseases worldwide.
View Article and Find Full Text PDFCytoprotective 3K3A-activated protein C and plasma: A comparison of therapeutics for the endotheliopathy of trauma.
J Trauma Acute Care Surg
January 2025
From the University of Colorado, Department of Surgery, Division Gastrointestinal, Trauma, and Endocrine Surgery, Aurora, CO (O.T., P.S., M.D., M.K., S.M., W.H., L.T.G., T.S., B.S., B.R., A.D., K.H., C.C.S., E.M., M.C.); The Ernest E Moore Shock Trauma Center at Denver Health, Denver Health Medical Center, Department of Surgery, Denver, CO (E.M.); and Scripps Research, Department of Molecular Medicine (L.M., J.G.).
Background: Both healthy plasma and cytoprotective aPC (3K3A-aPC) have been shown to mitigate the endotheliopathy of trauma (EoT), but optimal therapeutics remain unknown. Our aim was therefore to determine optimal therapies to mitigate EoT by investigating the effectiveness of 3K3A-aPC with and without plasma-based resuscitation strategies.
Methods: Electric cell-substrate impedance sensing (ECIS) was used to measure real-time permeability changes in endothelial cells.
Exploring the role of sporadic BRAF and KRAS mutations during colorectal cancer pathogenesis: A spotlight on the contribution of the endosome-lysosome system.
Cancer Lett
March 2024
Clinical and Health Sciences, University of South Australia, North Terrace, Adelaide, South Australia, Australia. Electronic address:
Article Synopsis
- Colorectal cancer's diverse characteristics make early diagnosis difficult, contributing to high mortality rates due to its complex genetic underpinnings.
- The adenoma-carcinoma and serrated polyp-carcinoma sequences are the primary pathways in sporadic colorectal cancer, influenced by specific genetic mutations like APC, KRAS, TP53, BRAF, and MLH1.
- These mutations affect the endosome-lysosome system, which is crucial for cancer development and colon function, highlighting its role in the variations of colorectal cancer pathology.
Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer.
Cell Chem Biol
October 2023
Pfizer, Oncology Research & Development, San Diego, CA 92121, USA. Electronic address:
KAT6A, and its paralog KAT6B, are histone lysine acetyltransferases (HAT) that acetylate histone H3K23 and exert an oncogenic role in several tumor types including breast cancer where KAT6A is frequently amplified/overexpressed. However, pharmacologic targeting of KAT6A to achieve therapeutic benefit has been a challenge. Here we describe identification of a highly potent, selective, and orally bioavailable KAT6A/KAT6B inhibitor CTx-648 (PF-9363), derived from a benzisoxazole series, which demonstrates anti-tumor activity in correlation with H3K23Ac inhibition in KAT6A over-expressing breast cancer.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!